Quantcast
Channel: Bristol-Myers Squibb Canada - News Releases - Cardiovascular
Viewing all articles
Browse latest Browse all 2

Onglyza® (saxagliptin) Achieves Primary Safety Endpoint, Demonstrating No Increased Risk for Cardiovascular Death, Heart Attack or Stroke in SAVOR Cardiovascular Outcomes Trial

0
0
• SAVOR provides information on cardiovascular safety for Onglyza in the wake of past questions about cardiovascular safety of type 2 diabetes treatments • SAVOR is the largest cardiovascular outcomes trial to study a diverse population of type 2 diabetes patients at high risk for cardiovascular events • Onglyza did not meet the primary efficacy endpoint of superiority to placebo • In additional analyses, patients treated with Onglyza had improved glycemic control over two years

Viewing all articles
Browse latest Browse all 2

Latest Images

Trending Articles





Latest Images